Hospitals in Barcelona and Toledo are investigating whether a wearable exoskeleton can support people in early rehabilitation after a traumatic spinal cord injury. The clinical study involves Hospital Vall d’Hebron, the Hospital Nacional de Parapléjicos and the Universität Lleida . According to the participating institutions, they are still seeking participants.
As Spanish media reported on 17 November, the hospitals are currently working with 15 patients: five in Barcelona and ten in Toledo. The study is examining use of the device during the first six months after injury. According to Catalan broadcaster 3Cat, earlier studies focused mainly on people with long-standing spinal cord injuries.
The Exoskelett ABLE was developed by Catalan company ABLE Human Motion. According to Hospital Vall d’Hebron, it is lighter and quicker to put on than conventional devices for robotic gait training. Software adjusts the support to each person’s functional abilities. The study will determine whether this results in a measurable treatment benefit.
Lluïsa Montesinos, head of the spinal cord injury unit at Hospital Vall d’Hebron, says the aim is to assess the clinical and biomechanical effects, as well as the effectiveness, of its use at this early stage. According to 3Cat, researchers want to examine changes in mobility and bone density, among other things, as well as effects on the heart and circulation. Universität Lleida is to assess the economic impact of the therapy.
According to the trial registry, participants are randomly assigned to one of two groups. One group receives rehabilitation with the exoskeleton, while the other receives conventional gait training. Depending on need, the aids used may include parallel bars, braces and walking aids. According to the registry, the manufacturer ABLE Human Motion is sponsoring the study.
The ongoing study does not show that the exoskeleton is superior to existing methods or enables people with spinal cord injuries to walk independently again. According to 3Cat’s report, the conclusions are due to be presented in 2028. Until results are available, claims about the procedure’s actual benefits and cost-effectiveness remain open.
Editor: Clara Simonichek (Article created with AI assistance).